Table 1. Baseline characteristics of HIV-negative controls and PLWH.
| Characteristic | HIV-negative participants | People living with HIV | ||||
|---|---|---|---|---|---|---|
| Overall N = 440 |
mRNA vaccines1 N = 341 (77.5%) |
Vector vaccines2 N = 99 (22.5%) |
Overall N = 1,154 |
mRNA vaccines1 N = 984 (85.3%) |
Vector vaccines2 N = 170 (14.7%) |
|
| Sex assigned at birth | ||||||
| Male | 126 (28.6%) | 104 (30.5%) | 22 (22.2%) | 987 (85.5%) | 839 (85.2%) | 148 (87.1%) |
| Female | 314 (71.4%) | 237 (69.5%) | 77 (77.8%) | 167 (14.5%) | 145 (14.8%) | 22 (12.9%) |
| Age category | ||||||
| 18–55 years | 352 (80.0%) | 284 (83.3%) | 68 (68.7%) | 703 (60.9%) | 674 (68.5%) | 29 (17.1%) |
| 56–65 years | 74 (16.8) | 43 (12.6%) | 31 (31.3%) | 291 (25.2%) | 157 (16.0%) | 134 (79.3%) |
| >65 years | 14 (3.2%) | 14 (4.1%) | 0 | 160 (13.9%) | 153 (15.6%) | 7 (4.1%) |
| On cART | ||||||
| Yes | NA | NA | NA | 1,142 (99.0%) | 972 (98.8%) | 170 (100%) |
| No | NA | NA | NA | 12 (1.0%) | 12 (1.2%) | 0 |
| Most recent plasma HIV viral load | ||||||
| <50 copies/mL | NA | NA | NA | 1,127 (97.7%) | 960 (97.6%) | 167 (98.2%) |
| ≥50 copies/mL | NA | NA | NA | 27 (2.3%) | 24 (2.4%) | 3 (1.8%) |
| Most recent CD4+ T-cell count | ||||||
| <250 cells/μL | NA | NA | NA | 41 (3.6%) | 35 (3.6%) | 6 (3.5%) |
| 250–500 cells/μL | NA | NA | NA | 224 (19.4%) | 189 (19.2%) | 35 (20.6%) |
| >500 cells/μL | NA | NA | NA | 889 (77.0%) | 760 (77.2%) | 129 (75.9%) |
| Nadir CD4+ T-cell count | ||||||
| <250 cells/μL | NA | NA | NA | 443 (38.4%) | 365 (37.1%) | 78 (45.9%) |
| 250–500 cells/μL | NA | NA | NA | 376 (32.6%) | 330 (33.5%) | 46 (27.1%) |
| >500 cells/μL | NA | NA | NA | 152 (13.2%) | 133 (13.5%) | 19 (11.2%) |
| Unknown | NA | NA | NA | 183 (15.9%) | 156 (15.9%) | 27 (15.9%) |
| Days between doses * | 28 (25–28) | 28 (25–28) | 56 (56–70) | 35 (35–36) | 35 (35–36) | 70 (49–77) |
| Days between second† vaccination and blood draw | 29 (27–33) | 28 (25–31) | 30 (28–32) | 30 (28–34) | 30 (28–34) | 30 (28–34) |
Data are n (%) or median (IQR).
1BNT162b2 or mRNA-1273.
2ChAdOx1-S or Ad26.COV2.S.
*Does not apply for Ad26.COV2.S.
†First and only vaccination for Ad26.COV2.S.
cART, combination antiretroviral therapy; IQR, interquartile range; NA, not applicable.